Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
huMNC2-CAR v2b (1XX modified)
- Development stage
- Phase 1
- Lead developer
- Minerva Biotechnologies
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
huMNC2-CAR v2b (1XX modified) is a preclinical chimeric antigen receptor (CAR) T-cell therapy developed by Minerva Biotechnologies. It is designed to target MUC1*, the cleaved, tumor-associated form of the MUC1 transmembrane protein, which is expressed on a wide variety of solid tumors. The '1XX' designation refers to a specific modification of the CD3-zeta signaling domain involving Tyrosine to Phenylalanine mutations. This modification is intended to calibrate T-cell signaling to reduce exhaustion and increase the persistence of the CAR T cells, potentially allowing for more effective recognition and killing of cancer cells, including those with low levels of antigen expression. The 'v2b' variant is part of Minerva's next-generation pipeline of CAR constructs optimized for treating MUC1*-positive solid tumors.
- Other names
- huMNC2-CAR v2b (1XX modified)MUC1*-CAR T cell therapy
02
Targets
MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on huMNC2-CAR v2b (1XX modified).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on huMNC2-CAR v2b (1XX modified).